| 1.965 -0.035 (-1.75%) | 11-05 11:21 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 2.77 | 1-year : | 3.24 |
| Resists | First : | 2.38 | Second : | 2.77 |
| Pivot price | 1.97  |
|||
| Supports | First : | 1.74 |
Second : | 1.36 |
| MAs | MA(5) : | 2.08 |
MA(20) : | 1.87 |
| MA(100) : | 1.45 |
MA(250) : | 1.48 |
|
| MACD | MACD : | 0.1 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 57.3 |
D(3) : | 73.1 |
| RSI | RSI(14): 53.6 |
|||
| 52-week | High : | 2.72 | Low : | 0.85 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ PACB ] has closed above bottom band by 41.2%. Bollinger Bands are 68.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 19 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 2.21 - 2.23 | 2.23 - 2.24 |
| Low: | 1.95 - 1.97 | 1.97 - 1.98 |
| Close: | 1.98 - 2 | 2 - 2.02 |
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides PacBio's Systems, which conduct, monitor, and analyse biochemical sequencing reactions; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. The company serves research institutions; commercial laboratories; genome centers; public health labs, hospitals and clinical research institutes, contract research organizations, and academic institutions; pharmaceutical companies; and agricultural companies. It markets its products through a direct sales force in North America and Europe, as well as through distribution partners in Asia, Europe, the Middle East, Africa, and Latin America. Pacific Biosciences of California, Inc. has a development and commercialization agreement with Invitae Corporation. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
Wed, 05 Nov 2025
PacBio (PACB): Valuation in Focus After World-First NMPA Approval for Clinical Long-Read Sequencer in China - Yahoo Finance
Wed, 05 Nov 2025
PacBio (NASDAQ: PACB) announces study detecting all 125 variants across 11 regions - Stock Titan
Tue, 04 Nov 2025
PacBio (PACB) Achieves Milestone with Approval in China for Sequ - GuruFocus
Tue, 04 Nov 2025
Pacific Biosciences (PACB) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance Measures - Nasdaq
Tue, 04 Nov 2025
PacBio (NASDAQ: PACB) secures NMPA Class III approval, first long-read clearance - Stock Titan
Mon, 03 Nov 2025
Pacific Biosciences of California Inc expected to post a loss of 15 cents a share - Earnings Preview - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 300 (M) |
| Shares Float | 298 (M) |
| Held by Insiders | 7.8 (%) |
| Held by Institutions | 57.1 (%) |
| Shares Short | 34,510 (K) |
| Shares Short P.Month | 45,550 (K) |
| EPS | -2.24 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.2 |
| Profit Margin | 0 % |
| Operating Margin | -112.8 % |
| Return on Assets (ttm) | -33.3 % |
| Return on Equity (ttm) | -190 % |
| Qtrly Rev. Growth | 10.3 % |
| Gross Profit (p.s.) | 0.14 |
| Sales Per Share | 0.51 |
| EBITDA (p.s.) | -0.76 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -150 (M) |
| Levered Free Cash Flow | 67 (M) |
| PE Ratio | -0.86 |
| PEG Ratio | 0 |
| Price to Book value | 9.57 |
| Price to Sales | 3.68 |
| Price to Cash Flow | -3.85 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |